Business Context and Reporting Period
Company: Microbot Medical Inc. (MBOT)
Filing Type: Form 8-K (Current Report)
Date of Report: September 8, 2025
Principal Executive Offices: Hingham, MA
This filing reports a significant regulatory milestone and upcoming investor conference participation. The Company is a Delaware corporation listed on the NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory clearance and corporate events rather than financial performance data.
Material Changes and Events
- FDA Clearance: The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the LIBERTY® Endovascular Robotic System.
- Product Distinction: LIBERTY® is the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
- Commercialization Status: Clearance enables the Company to commence commercialization in the U.S. and pursue global market entry.
- Market Opportunity: The Company aims to penetrate the approximately 2.5 million annual U.S. peripheral vascular procedures.
Guidance, Outlook, and Management Commentary
Strategic Outlook: Management expects to complete final commercial activities contingent on marketing clearance. The goal is to transform the field by enabling accessibility to advanced robotics without traditional capital equipment constraints or dedicated infrastructure.
Investor Conference: The Company will attend the H.C. Wainwright Annual Investor Conference in New York (September 8-10, 2025). CEO Harel Gadot is scheduled to present live on September 9, 2025, at 9:00 am ET.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ due to numerous factors, and the Company assumes no obligation to update these statements except as required by law.
Key Facts for Investor Verification
- Confirm the specific terms and limitations of the 510(k) clearance for the LIBERTY® system.
- Verify the timeline for the commencement of commercial sales and initial revenue recognition.
- Review the Company's cash position and burn rate to assess runway for commercialization efforts.
- Monitor the execution of the go-to-market strategy for the 2.5 million procedure addressable market.
- Check for any subsequent updates regarding global regulatory approvals outside the U.S.